ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.34T | 35.31% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $682.52B | 17.95% |
3TMO | THERMO FISHER SCIENTIFIC INC | Healthcare | $259.15B | 6.81% |
4MDT | MEDTRONIC PLC | Healthcare | $129.18B | 3.40% |
5MCK | MCKESSON CORP | Healthcare | $124.35B | 3.27% |
6REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $98.40B | 2.59% |
7MRNA | MODERNA INC | Healthcare | $93.61B | 2.46% |
8ELV | ELEVANCE HEALTH INC | Healthcare | $92.88B | 2.44% |
9CAH | CARDINAL HEALTH INC | Healthcare | $64.29B | 1.69% |
10EW | EDWARDS LIFESCIENCES CORP | Healthcare | $60.84B | 1.60% |
11IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 1.45% |
12HUM | HUMANA INC | Healthcare | $53.29B | 1.40% |
13TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $50.93B | 1.34% |
14ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 1.25% |
15IQV | IQVIA HOLDINGS INC | Healthcare | $44.68B | 1.17% |
16RPRX | ROYALTY PHARMA PLC | Healthcare | $39.56B | 1.04% |
17CNC | CENTENE CORP | Healthcare | $34.79B | 0.91% |
18MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $34.43B | 0.91% |
19LH | LABCORP HOLDINGS INC | Healthcare | $30.23B | 0.79% |
20ROIV | ROIVANT SCIENCES LTD | Healthcare | $28.98B | 0.76% |
21DGX | QUEST DIAGNOSTICS INC | Healthcare | $28.57B | 0.75% |
22VTRS | VIATRIS INC | Healthcare | $23.70B | 0.62% |
23THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 0.60% |
24ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $19.79B | 0.52% |
25MEDP | MEDPACE HOLDINGS INC | Healthcare | $18.37B | 0.48% |
26RVTY | REVVITY INC | Healthcare | $17.53B | 0.46% |
27NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.15B | 0.45% |
28EXEL | EXELIXIS INC | Healthcare | $17.04B | 0.45% |
29GKOS | GLAUKOS CORP | Healthcare | $14.56B | 0.38% |
30EHC | ENCOMPASS HEALTH CORP | Healthcare | $13.82B | 0.36% |
31ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $13.25B | 0.35% |
32TECH | BIO-TECHNE CORP | Healthcare | $11.44B | 0.30% |
33KYMR | KYMERA THERAPEUTICS INC | Healthcare | $10.86B | 0.29% |
34PCVX | VAXCYTE INC | Healthcare | $10.24B | 0.27% |
35OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 0.26% |
36HNGE | HINGE HEALTH INC | Healthcare | $9.83B | 0.26% |
37SYRE | SPYRE THERAPEUTICS INC | Healthcare | $9.77B | 0.26% |
38TGTX | TG THERAPEUTICS INC | Healthcare | $9.76B | 0.26% |
39HQY | HEALTHEQUITY INC | Healthcare | $8.52B | 0.22% |
40PACS | PACS GROUP INC | Healthcare | $7.62B | 0.20% |
41KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $7.56B | 0.20% |
42CHE | CHEMED CORP | Healthcare | $7.16B | 0.19% |
43ORKA | ORUKA THERAPEUTICS INC | Healthcare | $7.12B | 0.19% |
44KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 0.18% |
45TFX | TELEFLEX INC | Healthcare | $6.07B | 0.16% |
46RDNT | RADNET INC | Healthcare | $5.99B | 0.16% |
47HAE | HAEMONETICS CORP | Healthcare | $5.59B | 0.15% |
48CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $5.44B | 0.14% |
49LFST | LIFESTANCE HEALTH GROUP INC | Healthcare | $5.38B | 0.14% |
50HTFL | HEARTFLOW INC | Healthcare | $5.21B | 0.14% |
51EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 0.13% |
52LIVN | LIVANOVA PLC | Healthcare | $4.97B | 0.13% |
53ICUI | ICU MEDICAL INC | Healthcare | $4.43B | 0.12% |
54PLSE | PULSE BIOSCIENCES INC | Healthcare | $3.84B | 0.10% |
55IRON | DISC MEDICINE INC | Healthcare | $3.79B | 0.10% |
56OGN | ORGANON & CO | Healthcare | $3.65B | 0.10% |
57SGRY | SURGERY PARTNERS INC | Healthcare | $3.48B | 0.09% |
58GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $3.13B | 0.08% |
59XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $3.04B | 0.08% |
60VCEL | VERICEL CORP | Healthcare | $2.93B | 0.08% |
61XNCR | XENCOR INC | Healthcare | $2.86B | 0.08% |
62PGNY | PROGYNY INC | Healthcare | $2.69B | 0.07% |
63MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.45B | 0.06% |
64UFPT | UFP TECHNOLOGIES INC | Healthcare | $2.37B | 0.06% |
65PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.06% |
66PVLA | PALVELLA THERAPEUTICS INC | Healthcare | $2.24B | 0.06% |
67REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.05% |
68VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 0.05% |
69TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | Healthcare | $2.05B | 0.05% |
70CERT | CERTARA INC | Healthcare | $1.82B | 0.05% |
71ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.05% |
72HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 0.04% |
73TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.04% |
74CNMD | CONMED CORP | Healthcare | $1.50B | 0.04% |
75USPH | U S PHYSICAL THERAPY INC | Healthcare | $1.47B | 0.04% |
76PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.04% |
77SGP | SPYGLASS PHARMA INC | Healthcare | $1.11B | 0.03% |
78SIBN | SI-BONE INC | Healthcare | $1.09B | 0.03% |
79KIDS | ORTHOPEDIATRICS CORP | Healthcare | $851M | 0.02% |
80DCTH | DELCATH SYSTEMS INC | Healthcare | $744M | 0.02% |
81SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $679M | 0.02% |
82SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.02% |
83NRC | NRC HEALTH | Healthcare | $565M | 0.01% |
84RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.01% |
85DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $503M | 0.01% |
86CARL | CARLSMED INC | Healthcare | $474M | 0.01% |
87TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.01% |
88INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $296M | 0.01% |
89DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.01% |
90RLYB | RALLYBIO CORP | Healthcare | $84M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $3.80T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 81% toward Growth. +1% unclassified (9 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 90 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 90 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 29.9% | 29.9% |
| 3 yearsp.a. | 11.7% | -8.0% |
| 5 yearsp.a. | 6.6% | -3.7% |
| 10 yearsp.a. | 9.6% | -4.7% |
| Since inceptionp.a. | 7.8% | -11.7% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 31.9% | 33.9% |
| 2025 | 12.7% | -7.3% |
| 2024 | -7.2% | -15.8% |
| 2023 | -5.7% | -35.9% |
| 2022 | -1.5% | 10.5% |
| 2021 | 5.5% | -1.5% |
| 2020 | 16.8% | -32.7% |
| 2019 | 17.5% | -6.7% |
| 2018 | 14.3% | 28.8% |
| 2017 | 19.3% | 6.2% |
| 2016 | -0.8% | 19.8% |
| 2015 | 0.8% | 1.6% |
| 2014 | 22.8% | -18.9% |
| 2013 | 38.1% | -6.5% |
| 2012 | 17.8% | -21.9% |
| 2011 | 13.0% | 20.3% |
| 2010 | 2.0% | -15.4% |
| 2009 | 9.2% | -42.4% |
| 2008 | -17.9% | -27.8% |
| 2007 | 17.3% | 14.4% |
| 2006 | 5.1% | -6.9% |
| 2005 | 14.0% | 19.1% |
| 2004 | 7.6% | -16.0% |
| 2003 | 20.9% | -31.1% |
| 2002 | -19.9% | 15.1% |
| 2001 | -16.5% | -31.2% |
| 2000 | 28.9% | -71.7% |
| 1999 | -0.9% | -1.8% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare 52-Week High Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a 52-Week High signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.